Oramed Q2 2026: $116.5M Net Income Fueled by Alpha Tau Surge, Cash Drops to $15.2M
ORMP has more than doubled off its 52-week low of $1.975.
Summary
Oramed reported $116.5 million in net income for H1 2026, almost entirely from a non-cash revaluation of its Alpha Tau investment. Cash reserves dropped to $15.2 million, and the company faces a critical September 30 deadline to collect $35.4 million from Scilex.
Key Events · Earnings and Guidance · ORMP
-
Alpha Tau Revaluation Drives Net Income
An unrealized gain of $133.4 million on the Alpha Tau investment boosted net income to $116.5 million for H1 2026. Alpha Tau shares rose from $4.95 to $12.58, increasing the stake's fair value to $182 million.
-
Cash Reserves Plummet
Cash and equivalents fell to $15.2 million from $45.9 million at year-end 2025, driven by a $10.4 million dividend payment and $15.2 million in net investing outflows.
-
Scilex Debt in Jeopardy
Scilex owes Oramed $35.4 million across Tranche A and B notes, with a $5 million payment due July 31, 2026 not yet received. Full payment is due September 30, 2026, or Scilex must deliver registered shares.
-
Lifeward Transaction Closed
Oramed now holds 45% of Lifeward (valued at $9.6 million) and $9 million in senior secured convertible notes. Lifeward reported a $10.8 million net loss in Q1 2026.
Analysis · ORMP · Life Sciences
A $133.4 million unrealized gain on its Alpha Tau stake dominates Oramed's Q2 2026 results, more than doubling the investment's value to $182 million. This non-cash mark-to-market gain masks an operating loss of $6.4 million and a sharp cash burn — reserves fell from $45.9 million to $15.2 million in six months, partly due to a $10.4 million dividend payment. Now an investment holding entity with no operating revenue, the company's liquidity hinges on monetizing its portfolio. The Scilex debt situation remains precarious: a $5 million payment due July 31, 2026 was not received, and the full $35.4 million in obligations must be settled by September 30, 2026 or converted to Scilex stock. The Lifeward transaction closed, giving Oramed 45% ownership and $9 million in convertible notes, but Lifeward itself lost $10.8 million in Q1 2026. Subsequent Nano share sales raised $12.7 million, providing some near-term relief.
At the time of this filing, ORMP was trading at $4.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $174.7M. The 52-week trading range was $1.98 to $5.19. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.